In a prospective, double‐blind, randomised trial of carvedilol effects in preventing chemotherapy‐induced cardiotoxicity, the authors intended to assess the effectiveness of carvedilol in an HER‐2‐negative breast cancer group treated with anthracycline, cyclophosphamide and taxane. The gene discussed is ERBB2; the disease is breast cancer.